BBOT
BridgeBio Oncology Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.64
−2.37%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-56.4%
Return on equity
-48.3%
Return on assets
-61.1%
Return on invested capital
0.00x
Asset turnover
-$193.1M
Cash from operations
$2.82
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026